Shared on01 Aug 25Fair value Decreased 13%
Despite improved revenue growth projections and a lower future P/E multiple, Neogen's consensus analyst price target has been cut from $7.50 to $6.50, highlighting a more cautious valuation outlook. What's in the News Neogen reported a goodwill impairment charge of $597.9 million for the three months ended May 31, 2025.